Clinical advantages of a newly launched anti-thrombotic PMMA membrane for the nutritional status and dialysis-related symptoms in older chronic dialysis patients: a multicenter pilot study

Table 4 Secondary outcomes

Items		n	0	3	6	9	12
DW (kg)	NF	15	52.1 ± 9.2	52.5 ± 8.9	52.5 ± 8.8	52.0 ± 8.8	52.0 ± 9.0
DW (kg)	Cont	14	56.2 ± 11.0	56.4 ± 10.9	56.6 ± 10.9	56.5 ± 11.0	56.4 ± 11.1
nPCR (g/kg/day)	NF	15	0.95 ± 0.15	0.87 ± 0.15	0.86 ± 0.20	0.75 ± 0.15^{***, &&, ††}	0.83 ± 0.16^{***, ‡}
nPCR (g/kg/day)	Cont	13	0.86 ± 0.20	0.89 ± 0.22	0.86 ± 0.20	0.83 ± 0.22	0.87 ± 0.24
%CGR (%)	NF	15	124.4 ± 17.3	126.4 ± 13.2	124.3 ± 15.7^#	124.6 ± 19.2^#	117.7 ± 20.7^&
%CGR (%)	Cont	13	107.4 ± 26.9	109.4 ± 28.5	106.5 ± 25.3	106.3 ± 25.5	98.2 ± 30.8^&
Arm circumference (cm)	NF	15	25.0 ± 3.1	24.8 ± 3.1	24.2 ± 3.0	24.9 ± 3.0	25.6 ± 3.0
Arm circumference (cm)	Cont	13	25.0 ± 3.2	24.9 ± 3.0	25.4 ± 3.4	24.9 ± 2.1	25.1 ± 3.1^‡
CRP (mg/dL)	NF	15	0.14 ± 0.11	0.26 ± 0.26	0.30 ± 0.48	0.11 ± 0.08^&	0.23 ± 0.16^‡‡
CRP (mg/dL)	Cont	13	0.24 ± 0.31	0.18 ± 0.23	0.16 ± 0.22	0.24 ± 0.34	0.34 ± 0.62
dialysis-related symptoms	NF	15	6 (1–16)	4 (1–16)	5 (0–12)	4 (0–11)	3^$ (0–11)
dialysis-related symptoms	Cont	14	5 (0–13)	4 (0–13)	4.5 (0–17)	4.5 (0–15)	4.5 (0–13)

DW, nPCR, %CGR, arm circumference, and CRP are presented as the mean ± standard deviation. Dialysis-related symptoms are presented as the median (minimum–maximum values)
Unpaired t test: #, p < 0.05; NF group vs. Cont group
Paired t test: ***, p < 0.001 vs. 0 months; &, p < 0.05 vs. 3 months; &&, p < 0.01 vs. 3 months; ††, p < 0.01 vs. 6 months; ‡, p < 0.05 vs. 9 months; ‡‡, p < 0.01 vs. 9 months
Friedman test: $, p < 0.05 vs. 0 months
NF NF group, Cont control group, DW dry weight, nPCR normalized protein catabolism rate, CGR creatinine generation rate, CRP C-reactive protein

ISSN: 2059-1381